Mirum Pharmaceuticals Inc (MIRM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Mirum Pharmaceuticals Inc (MIRM) Stock Forecast
Analysts expect Mirum Pharmaceuticals (MIRM) to earn -$15.67 per share in the fiscal year ending Dec 31, 2026, on revenue of $717.61M. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.32.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.71, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 28.6% |
| Buy | 10 | 71.4% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 21.0%.
- Fiscal year ending Dec 31, 2026
- -$15.67
- EPS consensus, revenue $717.61M
- Fiscal year ending Dec 31, 2027
- $0.32
- EPS consensus, revenue $868.56M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$15.67 | -$15.67 to -$15.67 | 1 | $717.61M | $715.00M to $719.90M | 11 |
| Dec 31, 2027 | $0.32 | $0.32 to $0.32 | 1 | $868.56M | $791.60M to $948.17M | 12 |
Quarterly Estimates
The EPS consensus falls from -$0.59 for the quarter ending Dec 31, 2026 to -$0.67 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.59 | -$1.15 to -$0.12 | 15 | $198.00M | $178.36M to $207.42M | 14 |
| Mar 31, 2027 | -$0.67 | -$0.97 to -$0.43 | 7 | $198.68M | $188.36M to $210.60M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 60 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$15.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$15.67 | -$15.23 | -$15.14 | -$15.14 | N/A | N/A |
| Fiscal year ending Dec 31, 2027 | $0.32 | -$0.71 | -$0.35 | -$0.35 | -$0.04 | N/A |
| Quarter ending Mar 31, 2027 | -$0.67 | -$0.33 | -$0.33 | -$0.33 | -$0.34 | N/A |
Frequently Asked Questions About MIRM
What is the MIRM stock forecast?
Consensus analyst estimates put Mirum Pharmaceuticals's EPS at -$15.67 for the fiscal year ending Dec 31, 2026, on revenue of $717.61M. The consensus rating from 14 analysts is Buy.
How do analysts rate MIRM stock?
Of 14 analysts covering Mirum Pharmaceuticals, 4 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MIRM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$15.67, with estimates from -$15.67 to -$15.67 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.32, with estimates from $0.32 to $0.32 from 1 analyst.
What revenue do analysts expect from Mirum Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $717.61M, with estimates from $715.00M to $719.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $868.56M, with estimates from $791.60M to $948.17M.
How many analysts cover MIRM?
14 analysts rate Mirum Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
MIRM pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts